News | December 18, 2007

Abiomed Gets FDA Clearance for Circulatory Support System

December 19, 2007 - Abiomed Inc. today announced that it has received approval from the FDA for U.S. commercial distribution of the Company's combination iPulse Circulatory Support System, enabling Abiomed to enter the $200 million intra-aortic balloon market.

The iPulse drives Abiomed and other manufacturer’s intra-aortic balloons (IAB), Abiomed’s BVS 5000 and AB5000 ventricular assist devices (VAD), as well as new products Abiomed may offer in the future. These products are designed to treat patients suffering from acute heart failure by offering various levels of cardiac support, whether minimal, moderate or full bi-ventricular,v to potentially recover the patient’s native heart. The iPulse is the first console with the capability to provide either VAD or IAB support in the catheterization lab and surgery suite.

"This is an important milestone for Abiomed and an opportune time to be entering the $200 million IAB market," said Michael R. Minogue, Chairman, CEO and president of Abiomed. “We believe the iPulse will create new opportunities in open heart hospitals and help fuel growth in our AB5000 disposables.”

There are an estimated 160,000 IAB’s used globally each year with approximately 110,000 annual U.S. procedures. Over 1,000 open heart hospitals, which include approximately 100 transplant hospitals, could potentially use an IAB today as their initial level of circulatory support in the U.S. Based on Abiomed’s internal testing during 510(k) clearance of its IAB, the Company believes its IAB has the fastest inflate-deflate time, and best performance relative to abrasion resistance and triggering. The iPulse should be a more cost-effective system for heart hospitals by supporting procedures with associated Medicare reimbursement that extends across four diagnostic related groups (DRGs) ranging from approximately $20,000 to $215,000 per patient stay.

The current installed base of Abiomed’s AB5000 Circulatory Support System, prior to the approval of the iPulse, is comprised of approximately 50 percent of the U.S. transplant hospitals and approximately 20 percent of the U.S. open heart hospitals. Abiomed’s iPulse is also approved in Europe under CE-mark.

For more information:

Related Content

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump
News | Intra-Aortic Balloon Pumps (IABP) | September 24, 2018
September 24, 2018 — Getinge is voluntarily initiating a worldwide recall involving a field correction of approximate
Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018
June 6, 2018 — Maquet Datascope Corp.
An example of an intra-aortic balloon pump (IABP) from Maquet. The results of the SEMPER FI trial. #europcr2018 #Europcr

An example of an intra-aortic balloon pump (IABP) from Maquet. 

Feature | Intra-Aortic Balloon Pumps (IABP) | May 31, 2018
May 31, 2018 — The results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia
FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Impella CP heart pump, TCT 2016, intra-aortic balloon counterpulsation, IABP, clinical study
News | Intra-Aortic Balloon Pumps (IABP) | January 03, 2017 | Dave Fornell
The Impella CP heart pump (Abiomed) demonstrated no improvement in mortality for patients with myocardial infarction...
Teleflex, Arrow IAB catheter, intra-aortic balloon pump, worldwide recall
News | Intra-Aortic Balloon Pumps (IABP) | March 11, 2016
Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous...
Overlay Init